June 9, 2013
Scientists identify potential drug target for treatment-resistant anemias
Researchers at Whitehead Institute have identified a key target protein of glucocorticoids, the drugs that are used to increase red blood cell production in patients with certain types of anemia, including those resulting from trauma, sepsis, malaria, kidney dialysis, and chemotherapy.
|
May 30, 2013 Protein complex in key cell-growth pathway could help predict response to cancer therapyWhitehead Institute researchers have identified a protein complex that, when mutated, sends the master growth regulatory pathway known as mTORC1 into overdrive. Researchers believe that mutations in this complex could serve as biomarkers to predict response to rapamycin treatment in cancer patients. |
May 9, 2013 Whitehead Member Peter Reddien named an HHMI InvestigatorThe Howard Hughes Medical Institute (HHMI) announced today that Whitehead Member Peter Reddien is among 27 biomedical researchers nationwide to be appointed as HHMI investigators. |
|
May 2, 2013 Scientists revolutionize the creation of genetically altered mice to model human diseaseUsing a bacteria-based technique, Whitehead Institute Founding Member Rudolf Jaenisch has efficiently created mouse models with multiple gene mutations in a matter of weeks. |
April 11, 2013 Genetic master controls expose cancers’ Achilles’ heelIn a surprising finding that helps explain fundamental behaviors of normal and diseased cells, Whitehead Institute scientists have discovered a set of powerful gene regulators dubbed “super-enhancers” that control cell state and identity. |
